Tesamorelin vs Tirzepatide
Side-by-side comparison of Tesamorelin and Tirzepatide: mechanism, half-life, dose range, safety profile, and vendor pricing.
Price snapshot
Tesamorelin
Tirzepatide
Tesamorelin
Tesamorelin is a stabilized synthetic analog of human growth hormone-releasing hormone (GHRH) — specifically the full 44-amino-acid GHRH sequence with a single N-terminal trans-3-hexenoyl fatty-acid modification. That…
Lowest listed price: $44.99 across 5 listings
Full Tesamorelin profileTirzepatide
Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist with a molecular weight of 4813.45 Da and CAS number 2023788-19-2. It is a 39-amino-acid…
Lowest listed price: $49.00 across 14 listings
Full Tirzepatide profileSide-by-side comparison
| Attribute | Tesamorelin | Tirzepatide |
|---|---|---|
| Category | Growth Hormone / IGF-1 Axis | Metabolic & Weight Loss |
| Research Stage | FDA Approved | FDA Approved |
| Mechanism of Action | Tesamorelin activates the same GHRH receptor (GHRHR) as endogenous GHRH and CJC-1295 / MOD-GRF 1-29, but with a distinct pharmacokinetic profile driven by its trans-3-hexenoyl N-terminal modification. 1. GHRH receptor agonism (Gs / cAMP / PKA / CREB pathway) -… | Dual GLP-1 and GIP Receptor Agonism Tirzepatide simultaneously activates two incretin receptors: the GLP-1 receptor and the GIP receptor. While the GLP-1 receptor component provides the well-established effects of GLP-1 agonism (glucose-dependent insulin… |
| Half-Life | 8 to 11 minutes in healthy subjects (EGRIFTA SV and EGRIFTA WR labels) | ~5 days (approximately 120 hours), enabled by C20 fatty diacid albumin-binding modification |
| Typical Dose Range | 1,000–2,000 mcg (1–2 mg) daily | 2500 mcg (2.5 mg) starting dose, titrated every 4 weeks through 5000, 7500, 10000, 12500, to 15000 mcg (15 mg) maximum weekly dose |
| Dosing Frequency | Once daily subcutaneous injection | Once weekly subcutaneous injection |
| Administration | subcutaneous | Subcutaneous (weekly) |
| Side Effects | Tesamorelin has a well-characterized side-effect profile from the FDA approval program, which is a significant advantage over non-approved GHRH analogs. Common (10% in Phase 3 trials) - Injection site reactions — erythema, pruritus, pain at site; most frequent… | Mild to moderate nausea (especially at initiation), headache, fatigue, constipation or diarrhea, abdominal distension. Injection site reactions. Rare: hypoglycemia, increased heart rate, pancreatitis. |
| Molecular Weight | 5135.9 Da | 4813.5 Da |
| Common Vial Sizes | 2mg, 10mg | 5mg, 10mg, 15mg |
Price History
3 data points- BM
- Half Nattys
- BHG Labs
Price History
3 data points- BM
- Half Nattys
- Ion Peptide
Tesamorelin: potential benefits
- Reduction of visceral adipose tissue (~15% at 26 weeks in the pivotal HIV trial; FDA-label indication)
- Reduction of hepatic fat content (NAFLD off-label indication)
- Higher IGF-1 (mean rise of about 81% at 26 weeks in the main Phase 3 trial, PMID 18057338)
- Preserved pulsatile GH release (vs continuous elevation with CJC-1295-DAC)
- Improved body composition (VAT down, lean mass preserved)
- Sustained VAT reduction through 52 weeks with continued dosing
- FDA-approved - the only GHRH secretagogue with that status
Tirzepatide: potential benefits
- Mean body weight reduction of 20.9% at 72 weeks on 15 mg for everyone randomized (treatment-regimen estimand), 22.5% in the efficacy estimand (SURMOUNT-1, PMID: 35658024)
- 36.2% of participants achieved greater than or equal to 25% body weight loss (PMID: 35658024)
- Significant HbA1c reduction in type 2 diabetes (up to 2.4% at 40 weeks in the SURPASS-5 add-on-to-insulin trial) (PMID: 35133415)
- Potentially superior lean mass preservation versus GLP-1-only agents due to GIP component
- Dual incretin mechanism providing complementary metabolic benefits
- Improved lipid profiles including triglycerides, LDL cholesterol, and HDL cholesterol
- Reduction in waist circumference and markers of visceral adiposity (PMID: 37840095)
Frequently asked
What's the difference between Tesamorelin and Tirzepatide?
Tesamorelin is a growth hormone / igf-1 axis that tesamorelin activates the same ghrh receptor (ghrhr) as endogenous ghrh and cjc-1295 / mod-grf 1-29, but with a distinct pharmacokinetic profile driven by its trans-3-hexenoyl…. Tirzepatide is a metabolic & weight loss that dual glp-1 and gip receptor agonism tirzepatide simultaneously activates two incretin receptors: the glp-1 receptor and the gip receptor. while the glp-1 receptor component…. The two differ in mechanism, half-life (8 to 11 minutes in healthy subjects (EGRIFTA SV and EGRIFTA WR labels) vs ~5 days (approximately 120 hours), enabled by C20 fatty diacid albumin-binding modification), and typical dose range.
Which has the longer half-life, Tesamorelin or Tirzepatide?
Tesamorelin has a half-life of 8 to 11 minutes in healthy subjects (EGRIFTA SV and EGRIFTA WR labels). Tirzepatide has a half-life of ~5 days (approximately 120 hours), enabled by C20 fatty diacid albumin-binding modification. Longer half-lives generally mean less frequent dosing but slower on/off kinetics.
Which is cheaper, Tesamorelin or Tirzepatide?
Lowest listed price on BodyHackGuide: Tesamorelin from $44.99, Tirzepatide from $49.00. Prices are pulled from the vendor listings tracked on BHG and change frequently. See the compare tables on each compound page for the current set of offers.
Can you stack Tesamorelin and Tirzepatide?
Stacking depends on mechanism overlap, safety profile, and goals. Tesamorelin and Tirzepatide should only be stacked after reviewing each compound's individual protocol page, side effect profile, and any published interaction data. Use the BodyHackGuide stack builder for a structured review before combining research compounds.
See current vendor prices
Listings from the vendors we track. Prices change often, so check the vendor before you buy.
Before you buy Tesamorelin or Tirzepatide
Check the vendor trust score. Every supplier we track is rated 0-100 on COA verification, payment transparency, shipping, reviews, and listings: one published, reproducible methodology, applied to every vendor.
Related comparisons
Research use only. BodyHackGuide is a research and price-comparison reference. The compounds discussed on this page are not approved by the FDA for human consumption and are sold strictly for laboratory research. Prices shown are pulled from vendor listings tracked on BHG and are subject to change. Every vendor is ranked on the same public, reproducible methodology. See editorial standards and affiliate disclosure.